carcinoma

Documents about carcinoma

• HPV Vaccine, Imiquimod, and Metformin Combination Trial#249558ClinicalTrials.gov
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform#121327ClinicalTrials.gov
• Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma#127607ClinicalTrials.gov
• ARID1A and/or KDM6A Mutation and CXCL13 Expression#252990ClinicalTrials.gov
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer#283048ClinicalTrials.gov
• NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery#245503ClinicalTrials.gov
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma#217004ClinicalTrials.gov
• Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)#67883ClinicalTrials.gov
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer#261525ClinicalTrials.gov
• Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma#307460ClinicalTrials.gov
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)#201773ClinicalTrials.gov
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors#180367ClinicalTrials.gov
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers#300257ClinicalTrials.gov
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma#234418ClinicalTrials.gov
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy#332763ClinicalTrials.gov
• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer#279520ClinicalTrials.gov
• Sorafenib in Advanced Hepatocellular Carcinoma#6866OpenAlex
• Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)#18616ClinicalTrials.gov
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers#256862ClinicalTrials.gov
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer#28329ClinicalTrials.gov
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer#184800ClinicalTrials.gov
• Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion#148744ClinicalTrials.gov
• Renal Cell Carcinoma Microenvironment Discovery Project#180401ClinicalTrials.gov
• Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma#241596ClinicalTrials.gov
• Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma#329520ClinicalTrials.gov
• Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma#329546ClinicalTrials.gov
• Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer#234434ClinicalTrials.gov
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer#28310ClinicalTrials.gov
• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer#146462ClinicalTrials.gov
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer#325301ClinicalTrials.gov
• Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer#146473ClinicalTrials.gov
• Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma#180374ClinicalTrials.gov
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin#208448ClinicalTrials.gov
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer#121329ClinicalTrials.gov
• Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel#230434ClinicalTrials.gov
• Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer#329485ClinicalTrials.gov
• Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial#127569ClinicalTrials.gov
• Tislelizumab and Radiotherapy for Recurrent Cervical Cancer#287534ClinicalTrials.gov
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma#272363ClinicalTrials.gov
• Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma#126056ClinicalTrials.gov
• Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma#136344ClinicalTrials.gov
• Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma#140980ClinicalTrials.gov
• Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)#184861ClinicalTrials.gov
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy#303573ClinicalTrials.gov
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors#332738ClinicalTrials.gov
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma#245487ClinicalTrials.gov
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma#290974ClinicalTrials.gov
• DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma#121330ClinicalTrials.gov
• Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma#121334ClinicalTrials.gov
• Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma#123437ClinicalTrials.gov